Top 10 Biologics Sales Top $41 billion

September 9, 2009

Sales of the Top 10 biotech drugs exceeded $41.5 billion in 2008, according to a new report issued by BioWorld Today.

Sales of the Top 10 biotech drugs exceeded $41.5 billion in 2008, according to a new report issued by BioWorld Today. Amgen’s Enbrel topped the list with worldwide sales of $5.9 billion, followed by Genentech Rituxan ($5.08 billion), Abbott’s Humira ($4.5 billion) and Genentech’s Avastin ($4.5 billion) Genentech and Amgen both have 4 drugs in the top 25 with total sales of Genentech drugs reaching $15.7 billion in 2008 and Amgen’s totaling $14.9 billion.

Top 25 Biotech Drugs

1. Enbrel (Amgen)
2. Rituxan (Genentech)
3. Humira (Abbott)
4. Avastin (Genentech)
5. Herceptin (Genentech)
6. Remicade (Johnson & Johnson)
7. Gleevec (Novartis)
8. Neulasta (Amgen)
9. Lantus (Sanofi-Aventis
10. Aranesp (Amgen)
11. Prevnar (Wyeth
12. Taxotere (Sanofi-Aventis)
13. Procrit/Eprex (Ortho Biotech)
14. Epogen (Amgen)
15. Copaxone (Teva)
16. Avonex (Biogen Idec)
17. Truvada (Gilead Sciences)
18. Lucentis (Genentech)
19. Humalog (Eli Lilly)
20. Rebif (Merck Serono)
21. Atripla (Gilead Sciences)
22. Erbitux (ImClone)
23. Cialis (Eli Lilly)
24. Betaseron (Bayer Schering)
25. Tracleer (Actelion)

Note: this article is based on a report issued by BioWorldToday. The full report can be found on the BioWorld web site.